Comparison of the Non-Nucleoside Reverse Transcriptase Inhibitor Lersivirine with its Pyrazole and Imidazole Isomers

Chemical Biology and Drug Design

Volumn 77, Issue 5, 2011, Pages 393-397

  Jones, Lyn H ^a   Allan, Gill ^a   Corbau, Romuald ^a   Middleton, Donald S ^a   Mowbray, Charles E ^a   Newman, Sandra D ^a   Phillips, Chris ^a   Webster, Rob ^a   Westby, Mike ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Drug design; Drug discovery; Structure based drug design

Indexed keywords

IMIDAZOLE; LERSIVIRINE; PYRAZOLE; RNA DIRECTED DNA POLYMERASE;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; ENZYME INHIBITION; ISOMER; LETTER; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; DRUG DESIGN; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; IMIDAZOLES; MICROSOMES, LIVER; MODELS, MOLECULAR; MUTATION; NITRILES; PYRAZOLES; RATS; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79954619855     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01113.x     Document Type: Letter

References (16)

1. Ivetac A., McCammon J.A. (2009) Elucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulations. J Mol Biol;388:644-658.
2. Mowbray C.E., Burt C., Corbau R., Gayton S., Hawes M., Perros M., Tran I., Price D.A., Quinton F.J., Selby M.D., Stupple P.A., Webster R., Wood A. (2009) Pyrazole NNRTIs 4: selection of UK-453, 061 (lersivirine) as a development candidate. Bioorg Med Chem Lett;19:5857-5860.
3. Corbau R., Mori J., Phillips C., Fishburn L., Martin A., Mowbray C.E., Panton W., Smith-Burchnell C., Thornberry A., Ringrose H., Knöchel T., Irving S., Westby M., Wood A., Perros M. (2010) Lersivirine: a non-nucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus-1. Antimicrob Agents Chemother;54:4451-4463.
4. Pelemans H., Esnouf R., De Clercq E., Balzarini J. (2000) Mutational analysis of Trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors. Mol Pharm;57:954-960.
5. Fattorusso C., Gemma S., Butini S., Huleatt P., Catalanotti B., Persico M., De Angelis M. et al. (2005) Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. design, synthesis and biological evaluation of novel, potent and broad spectrum NNRTIs with antiviral activity. J Med Chem;48:7153-7165.
6. Jones L.H., Allan G., Barba O., Burt C., Corbau R., Dupont T., Knöchel T. et al. (2009) Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridisation based on crystallographic overlays. J Med Chem;52:1219-1223.
7. Ren J., Nichols C., Bird L.E., Fujiwara T., Sugimoto H., Stuart D.I., Stammers D.K. (2000) Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J Biol Chem;275:14316-14320.
8. Lansdon E.B., Brendza K.M., Hung M., Wang R., Mukund S., Jin D., Birkus G., Kutty N., Liu X. (2010) Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J Med Chem;53:4295-4299.
9. Jones L.H., Allan G., Corbau R., Hay D., Middleton D.S., Mowbray C.E., Newman S., Perros M., Randall A., Vuong H., Webster R., Westby M., Williams D. (2008) Optimization of 5-aryloxyimidazole non-nucleoside reverse transcriptase inhibitors. Chem Med Chem;3:1756-1762.
10. Jones L.H., Dupont T., Mowbray C.E., Newman S. (2006) A concise and selective synthesis of novel 5-aryloxyimidazole NNRTIs. Org Lett;8:1725-1727.
11. Ryckmans T., Edwards M.P., Horne V., Correia A., Owen D.R., Thompson L.R., Tran I., Tutt M.F., Young T. (2009) Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: a lipophilic efficiency (LipE) analysis. Bioorg Med Chem Lett;19:4406-4409.
12. Leeson P.D., Springthorpe B. (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Disc;6:881-890.
13. Evans D.C., Watt A.P., Nicoll-Griffith D.A., Baille T.A. (2004) Drug-protein adducts: an industry perspective on minimising the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol;17:3-16.
14. Allan G., Davis J., Dickins M., Gardner I., Jenkins T., Jones H., Webster R., Westgate H. (2008) Pre-clinical pharmacokinetics of UK-453, 061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453, 061 in man. Xenobiotica;38:620-640.
15. Jones L.H., Summerhill N., Swain N., Mills J.E. (2010) Aromatic chloride to nitrile transformation: medicinal and synthetic chemistry. Med Chem Comm;1:309-318.
16. Fätkenheuer G., Straszewski S., Plettenburg A., Hackman F., Layton G., McFadyen L., Davis J., Jenkins T.M. (2009) Activity, pharmacokinetics and safety of lersivirine (UK-453, 061), a next generation non-nucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients. AIDS;818:2115-2122.